Dr. Federico Gaeta Ph.D. Net Worth

Dr. Federico Gaeta Ph.D. biography

Dr. Federico Gaeta Ph.D. is the Chief Scientific Officer at Medicinova Inc.

What's Dr D's mailing address?

Federico's mailing address filed with the SEC is C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA, 92037.

Insiders trading at Medicinova Inc

Over the last 18 years, insiders at Medicinova Inc have traded over $200,908 worth of Medicinova Inc stock and bought 459,744 units worth $1,581,779 . The most active insiders traders include Jeff Himawan, Masatsune Okajima и Yuichi Iwaki. On average, Medicinova Inc executives and independent directors trade stock every 95 days with the average trade being worth of $74,094. The most recent stock trade was executed by Hideki Nagao on 28 November 2022, trading 6,754 units of MNOV stock currently worth $15,197.

What does Medicinova Inc do?

pharmaceutical preparations

Medicinova Inc executives and stock owners

Medicinova Inc executives and other stock owners filed with the SEC include:

• Yuichi Iwaki,
  President, Chief Executive Officer, Director
• Kazuko Matsuda,
  Chief Medical Officer, Director
• Geoffrey O'brien,
  Vice President
• Dr. Yuichi Iwaki M.D., Ph.D.,
  Co-Founder, Pres, CEO & Exec. Director
• Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.,
  Chief Medical Officer & Director
• Hideki Nagao,
  Independent Director
• Carolyn Beaver,
  Director
• Edward Stepanow,
  Chief Financial Officer
• Jeffrey Himawan,
  Independent Chairman of the Board
• John O'Neil CPA,
  Controller
• Dr. David H. Crean Ph.D.,
  Chief Bus. Officer
• Dr. Federico Gaeta Ph.D.,
  Chief Scientific Officer
• Douglas G Paulin CPA, CPA,
  Chief Financial Officer
• Yutaka Kobayashi,
  Director
• Yoshio Ishizaka,
  Director
• Masatsune Okajima,
  VP and Head of Japanese Office
• Federico C.A. Gaeta,
  Chief Scientific Officer
• Tatsuo Izumi,
  Director
• Den Boom Esther Van,
  Chief Financial Officer
• Jeff Himawan,
  Director
• John K A Prendergast,
  Director
• Hiroaki Shigeta,
  Director
• Kirk William Johnson,
  Chief Scientific Officer
• Arlene Morris,
  Director
• Michael Denis Coffee,
  Chief Business Officer
• David D O'toole,
  Director
• Alan W Dunton,
  Director
• Shintaro Asako,
  VP and Chief Financial Officer
• Richard E Sr Gammans,
  Chief Development Officer
• Daniel Vapnek,
  Director
• Kenneth W Locke,
  Chief Scientific Officer
• Michael E Kalafer,
  Chief Medical Officer
• Nicole Lemerond,
  Director